Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
GNBT's Cash to Debt is ranked lower than
126% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. GNBT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GNBT' s 10-Year Cash to Debt Range
Min: 0.09  Med: 6.18 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -186.42
M-Score: -4.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROA (%) 11.61
GNBT's ROA (%) is ranked lower than
125% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. GNBT: 11.61 )
Ranked among companies with meaningful ROA (%) only.
GNBT' s 10-Year ROA (%) Range
Min: -180.14  Med: -97.10 Max: -0.02
Current: 11.61
-180.14
-0.02
ROC (Joel Greenblatt) (%) 13437.50
GNBT's ROC (Joel Greenblatt) (%) is ranked lower than
129% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. GNBT: 13437.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNBT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2112.71  Med: -555.71 Max: 711.11
Current: 13437.5
-2112.71
711.11
EBITDA Growth (3Y)(%) -100.00
GNBT's EBITDA Growth (3Y)(%) is ranked lower than
252% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. GNBT: -100.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GNBT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -100  Med: -24.05 Max: 108
Current: -100
-100
108
EPS Growth (3Y)(%) -66.50
GNBT's EPS Growth (3Y)(%) is ranked lower than
259% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. GNBT: -66.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GNBT' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.5  Med: -23.40 Max: 46.3
Current: -66.5
-66.5
46.3
» GNBT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT 6.42
GNBT's EV-to-EBIT is ranked lower than
460% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. GNBT: 6.42 )
Ranked among companies with meaningful EV-to-EBIT only.
GNBT' s 10-Year EV-to-EBIT Range
Min: -6.7  Med: -1.00 Max: -0.2
Current: 6.42
-6.7
-0.2
Current Ratio 0.12
GNBT's Current Ratio is ranked lower than
129% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. GNBT: 0.12 )
Ranked among companies with meaningful Current Ratio only.
GNBT' s 10-Year Current Ratio Range
Min: 0.02  Med: 2.02 Max: 36.05
Current: 0.12
0.02
36.05
Quick Ratio 0.12
GNBT's Quick Ratio is ranked lower than
129% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. GNBT: 0.12 )
Ranked among companies with meaningful Quick Ratio only.
GNBT' s 10-Year Quick Ratio Range
Min: 0.02  Med: 1.99 Max: 36.05
Current: 0.12
0.02
36.05

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 15.60
GNBT's Earnings Yield (Greenblatt) (%) is ranked lower than
131% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. GNBT: 15.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNBT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0  Med: 0.00 Max: 0
Current: 15.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Generex Biotechnology Corporation was incorporated in Delaware in September 1997. The Company is engaged mainly in the research and development of drug delivery systems and technologies. It has identified several large molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormones. It has focused its development efforts mainly on one pharmaceutical product, Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its proprietary hand-held aerosol spray applicator known as RapidMist. Its wholly-owned subsidiary, Antigen, concentrates on developing proprietary vaccine formulations that work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self-proteins and allergens). Its immunomedicine products are based on two platform technologies and are in the early stages of development. The Company has vaccine development efforts underway for seasonal influenza virus, HIV, HPV, melanoma, ovarian cancer, allergy and Type I diabetes mellitus. Its main competitors include: Pfizer, Eli Lilly, Novo Nordisk, Merck & Co., Inc., GlaxoSmithKline PLC, Novartis, Inc., and MedImmune Inc.
» More Articles for GNBT

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: TDG, GNBT, ADGE, HFC, AMSWA Jul 02 2012 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Weekly CFO Buys Highlight: GNBT, CTTC, COIN, AUMN, SOMH Oct 31 2010 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 
Generex Biotechnology Corp. (GNBT) CEO Anna E Gluskin buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) CFO Rose C Perri buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
Generex Announces Issuance of Buccal Insulin White Paper Aug 27 2015
Generex Announces Issuance of Buccal Insulin White Paper Aug 27 2015
Generex Announces Issuance of Buccal Insulin White Paper Aug 27 2015
Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project Aug 25 2015
Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project Aug 25 2015
Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project Aug 25 2015
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Aug 20 2015
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to... Jun 25 2015
Generex Announces Capital Investment Jun 24 2015
Generex Announces Capital Investment Jun 24 2015
Generex Announces Capital Investment Jun 24 2015
GENEREX BIOTECHNOLOGY CORP Financials Jun 11 2015
10-Q for Generex Biotechnology Corp. Jun 07 2015
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-Q, Quarterly Report Jun 05 2015
Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist™ Buccal Delivery... May 26 2015
Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist™ Buccal Delivery... May 26 2015
Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist™ Buccal Delivery... May 26 2015
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of... May 14 2015
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of... May 14 2015
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of... May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK